Telix Pharmaceuticals Limited

CHIA:TLX Stock Report

Market Cap: AU$8.3b

Telix Pharmaceuticals Valuation

Is TLX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TLX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TLX (A$24.86) is trading below our estimate of fair value (A$43.66)

Significantly Below Fair Value: TLX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TLX?

Key metric: As TLX is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TLX. This is calculated by dividing TLX's market cap by their current revenue.
What is TLX's PS Ratio?
PS Ratio12.8x
SalesAU$645.68m
Market CapAU$8.28b

Price to Sales Ratio vs Peers

How does TLX's PS Ratio compare to its peers?

The above table shows the PS ratio for TLX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average38.4x
PYC PYC Therapeutics
30.7x31.0%AU$676.6m
RAC Race Oncology
60.3x34.8%AU$241.2m
OCC Orthocell
55.8xn/aAU$296.7m
CUV Clinuvel Pharmaceuticals
6.7x21.4%AU$588.9m
TLX Telix Pharmaceuticals
12.8x21.5%AU$8.3b

Price-To-Sales vs Peers: TLX is good value based on its Price-To-Sales Ratio (12.8x) compared to the peer average (38.4x).

Price to Sales Ratio vs Industry

How does TLX's PS Ratio compare vs other companies in the AU Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
ARX Aroa Biosurgery
3.4x21.3%US$146.68m
IMC Immuron
3.6x59.7%US$11.18m
BNO Bionomics
2.4x-5.3%US$9.52m
CHM Chimeric Therapeutics
0.8xn/aUS$3.73m
TLX 12.8xIndustry Avg. 10.0xNo. of Companies8PS01632486480+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TLX is expensive based on its Price-To-Sales Ratio (12.8x) compared to the Australian Biotechs industry average (10x).

Price to Sales Ratio vs Fair Ratio

What is TLX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TLX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.8x
Fair PS Ratio9.9x

Price-To-Sales vs Fair Ratio: TLX is expensive based on its Price-To-Sales Ratio (12.8x) compared to the estimated Fair Price-To-Sales Ratio (9.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TLX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$24.86
AU$25.62
+3.0%
20.8%AU$33.40AU$17.00n/a9
Dec ’25AU$24.80
AU$25.62
+3.3%
20.8%AU$33.40AU$17.00n/a9
Nov ’25AU$21.44
AU$25.45
+18.7%
20.2%AU$33.40AU$17.00n/a9
Oct ’25AU$20.93
AU$25.05
+19.7%
20.8%AU$33.10AU$17.00n/a9
Sep ’25AU$18.56
AU$24.74
+33.3%
19.6%AU$32.30AU$17.00n/a9
Aug ’25AU$19.39
AU$24.72
+27.5%
18.6%AU$31.90AU$17.00n/a9
Jul ’25AU$18.03
AU$18.89
+4.8%
19.3%AU$26.00AU$13.90n/a7
Jun ’25AU$18.11
AU$17.47
-3.5%
22.5%AU$26.00AU$13.90n/a7
May ’25AU$14.68
AU$15.29
+4.1%
11.8%AU$19.30AU$13.52n/a7
Apr ’25AU$12.86
AU$14.88
+15.7%
12.1%AU$18.50AU$12.60n/a7
Mar ’25AU$11.98
AU$14.40
+20.2%
13.9%AU$18.50AU$12.43n/a7
Feb ’25AU$11.43
AU$13.47
+17.8%
10.4%AU$16.00AU$11.45n/a7
Jan ’25AU$10.05
AU$13.53
+34.7%
10.9%AU$16.00AU$11.45n/a7
Dec ’24AU$9.95
AU$13.37
+34.4%
8.1%AU$14.80AU$11.45AU$24.806
Nov ’24AU$9.01
AU$12.21
+35.5%
24.6%AU$14.80AU$5.26AU$21.447
Oct ’24AU$11.39
AU$12.38
+8.7%
24.4%AU$15.00AU$5.26AU$20.937
Sep ’24AU$10.81
AU$12.38
+14.5%
24.4%AU$15.00AU$5.26AU$18.567
Aug ’24AU$11.49
AU$12.20
+6.2%
24.2%AU$14.50AU$5.26AU$19.397
Jul ’24AU$11.21
AU$11.86
+5.8%
25.6%AU$14.50AU$5.26AU$18.037
Jun ’24AU$11.64
AU$10.99
-5.5%
28.2%AU$14.20AU$5.26AU$18.117
May ’24AU$10.46
AU$10.49
+0.3%
29.3%AU$14.20AU$5.26AU$14.686
Apr ’24AU$6.90
AU$9.68
+40.3%
18.2%AU$13.00AU$7.90AU$12.865
Mar ’24AU$6.82
AU$9.59
+40.6%
18.9%AU$13.00AU$7.90AU$11.985
Feb ’24AU$6.86
AU$9.32
+35.9%
20.1%AU$13.00AU$7.90AU$11.435
Jan ’24AU$7.28
AU$9.12
+25.3%
17.9%AU$12.30AU$7.90AU$10.055
Dec ’23AU$7.39
AU$9.12
+23.4%
17.9%AU$12.30AU$7.90AU$9.955

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 20:21
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Telix Pharmaceuticals Limited is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightBarclay Pearce Capital Pty Limited
John HesterBell Potter
Andrew PaineCLSA